INTRODUCTION {#s1}
============

After T cell antigen receptor activation, the fate of naïve T cells is determined to a large extent by the cytokine environment \[[@R1]--[@R4]\]. Naïve CD4^+^T cells differentiate into functionally distinct subsets, including IFNγ-producing T~H~1 cells, IL-4-producing T~H~2 cells, IL-17-producing T~H~17 cells, and induced regulatory T cells (iT~reg~); these cells are responsible for different types of T cell immunity and affect immune-mediated responses to disease \[[@R5]--[@R8]\] (Figure [1](#F1){ref-type="fig"}). Among these T cell subtypes, IL-9-producing T~H~9 cells were first described in 1994 \[[@R9]\] and defined in 2008 \[[@R10], [@R11]\]. Initially, T~H~9 cells were thought to be associated with T~H~2 responses and to arise from TGFβ-induced reprogramming of T~H~2 cells \[[@R12]--[@R14]\]. However, recent reports have shown that T~H~9 cells are involved in antimicrobial immunity \[[@R15], [@R16]\], autoimmune disease \[[@R17]--[@R19]\], colitis \[[@R20], [@R21]\], and even anti-tumor immunity \[[@R12], [@R22]\]. This review summarizes the emerging role of T~H~9 cells in immune-mediated diseases, with a special focus on several recent anti-tumor immunological studies.

![Differentiation of T cell lineages\
Naïve CD4^+^T cells are activated by T cell receptor (TCR) signaling and differentiate into various T cell lineages depending on the cytokine environment. Prototypical differentiation cytokine sets, corresponding specific transcriptional factors, and functional cytokine effects that regulate T~H~ cell fate and functions (including T~H~9 cells) are shown.](oncotarget-07-71001-g001){#F1}

T~H~9 CELL DIFFERENTIATION AND SIGNAL TRANSDUCTION {#s2}
==================================================

T~H~9 cell differentiation {#s2_1}
--------------------------

The cytokine milieu plays a crucial role in T cell differentiation. In addition to IL-4 and TGFβ \[[@R10], [@R11]\], IL-1 \[[@R23]\], IL-2 \[[@R24]\], IL-6 \[[@R25]\], IL-10 \[[@R26]\], IL-21 \[[@R27], [@R28]\], IL-23 \[[@R29]\], IL-25 \[[@R30]\], IL-33 \[[@R31]\], IFN-α/β \[[@R27]\], and thymic stromal lymphopoietin (TSLP) \[[@R32]\] promote IL-9 production in naïve T cells, while IFN-γ and IL-27 suppress IL-9 production \[[@R18]\]. For example, naïve CD4^+^T cells primed with IL-4 and TGFβ1 secrete IL-9 \[[@R9]\]. Compared to stimulation with TCR alone, the addition of TGFβ1 increased IL-9 production in murine CD4^+^T cells; IL-9 production was further increased by the addition of both TGFβ1 and IL-4, which, by itself, has scant effect \[[@R33]--[@R36]\]. A variety of cytokines are now known to affect Th9 cell differentiation and IL-9 production in T cells.T~H~9 cell development requires the integration of multiple signals, and a complex cytokine milieu is required for optimal IL-9 production; the balance of cytokine signals is therefore critical for inducing T~H~9 cell development and differentiation rather than the generation of other T-helper subsets.

Transcriptional control of T~H~9 cell differentiation {#s2_2}
-----------------------------------------------------

Certain transcription factors, including STAT \[[@R37]\], PU.1 \[[@R21], [@R38], [@R39]\], IRF1 \[[@R28]\], IRF4 \[[@R40]\], NF-kB \[[@R41]\], Bcl6 \[[@R42]\], and the Smad/Notch complex \[[@R43]\], directly interact with the *Il9* gene promoter to increase IL-9 production (Figure [2](#F2){ref-type="fig"}). Moreover, acetylation and H3K27 trimethylation, a suppressive chromatin modification, are increased at the IL-9 promoter in T~H~9 cells \[[@R39], [@R44]\], resulting in barely detectable IL-9 production in these cells compared to other CD4^+^T cell lineages.

![Transcriptional control of T~H~9 cell differentiation\
IL-4, TGFβ1, IL-2, TCR, and other stimuli induce the expression of downstream transcriptional factors, including STAT6, IRF4, BATF, SMAD3, TAK1-SIRT1-mTOR-HIF1α, PU.1, STAT5, Bcl6, NF-kB, and NFAT, that interact with *Il9* promoters to increase IL-9 expression and secretion.](oncotarget-07-71001-g002){#F2}

IL-4 and TGFβ1, and their downstream transcriptional targets, are required for T~H~9 cell differentiation \[[@R23], [@R45]\]. For example, IL-4-induced activation of STAT6 and the STAT6 target gene GATA3 are both required for T~H~9 differentiation, although GATA3 is more important for T~H~2 differentiation \[[@R13], [@R46]\]. Upon activation, phosphorylated STAT6 facilitates the transcription of GATA3 and IRF4 \[[@R47]\]. However, modest retrovirus transduction-induced expression of IRF4 and/or GATA3 did not rescue IL-9 secretion in STAT6-deficient CD4^+^T cells, indicating that additional factors are required for the STAT6-dependent transcriptional modulation of T~H~9 differentiation \[[@R46]\]. In addition, GATA3 transcription is activated in a STAT6-independent manner during T~H~9 differentiation. Notch1- and Notch2-deficient T~H~9 cells exhibit decreased IL-9 production; Jagged2 is able to induce IL-9 production in the presence of TGFβ1 alone in these cells, and exogenous IL-4 rescues Notch deficiency \[[@R48], [@R49]\]. The DNA-binding inhibitor Id3 inhibits IL-9 production in CD4^+^T cells in a GATA3-dependent manner \[[@R33]\]. Deletion of Id3 increases IL-9 production in CD4^+^T cells, indicating that Id3 also inhibits T~H~9 differentiation in an IL-4-GATA3-dependent manner. These data suggest that STAT6 signaling is not absolutely necessary for the induction of T~H~9 differentiation; Notch or Id3-mediated induction of GATA3 is sufficient.

TGFβ is also required for T~H~9 generation. Accordingly, the TGFβ downstream target factor SMAD is critical for T~H~9 cell differentiation. Binding of TGFβ to its receptor activates specific SMAD family members, and TGFβ-activated phosphor-SMAD3 directly binds to the *Il9* locus, the Notch intracellular domain (NICD), and RBP-Jk (recombination signal binding protein for immunoglobulin kappa J region) \[[@R10], [@R43]\]. In addition, TGFβ1 induces transcriptional factor PU.1 expression and inhibits the expression of T-bet, a T~H~1-specific transcriptional factor, thereby promoting T~H~9 differentiation \[[@R21], [@R39]\]. PU.1 is expressed specifically in subpopulations of T~H~2 cells with low IL-4 expression. PU.1-deficient T cells produce less IL-9, and ectopic expression of PU.1 increases IL-9 production. Reduced PU.1 expression in human IL-9-secreting T cell cultures also reduced IL-9 production. Mechanistic studies have shown that PU.1 likely influences T~H~9 differentiation by interfering with GATA3 activation or by recruiting the histone acetyltransferase (HAT) proteins Gcn5 and PCAF to the *Il9* locus \[[@R21], [@R38]\].

The TGFβ-activated kinase TAK1 is an important mediator of Smad-independent TGFβ signaling \[[@R50]\] and plays a key role in directing T~H~9 differentiation \[[@R33]\]. Our recent studies confirm that TAK1 inhibition reversed SIRT1 suppression, suggesting that a Smad-independent TAK1 signal is responsible for SIRT1 suppression during T~H~9 differentiation. SIRT1 deficiencies induced by either conditional deletion in mouse CD4^+^T cells or small interfering RNA (siRNA) in mouse or human T cells increased, while ectopic SIRT1 expression inhibited, IL-9 production. Additionally, glycolytic activation through the mTOR-hypoxia-inducible factor-1α (HIF1α) pathway was required for T~H~9 cell differentiation. SIRT1 may therefore function as a gatekeeper of the downstream mTOR-HIF1α axis (Figure [2](#F2){ref-type="fig"}). Furthermore, mTOR-HIF1α-IL-9 promoter transcriptional regulation coupled with modulation of glycolytic activity is selective for SIRT1-dependent T~H~9 cell differentiation \[[@R51]\].

Transcriptional factors downstream of IL-2 are critical for T~H~9 cell differentiation \[[@R24]\], and IL-2 deficient CD4^+^T cells do not produce IL-9. STAT5, a downstream target of IL-2, directly binds to the *Il9* locus and thus promotes T~H~9 cell differentiation. Mechanistic studies suggest that IL-2-STAT5 signaling inhibits B cell lymphoma 6 (Bcl6) expressions and T~H~17 cell generation, thereby promoting T~H~9 cell differentiation \[[@R24], [@R42]\].

The transcription factors NF-kB and NFAT also modulate T~H~9 cell differentiation. Ligation of OX40 triggers sustained activation of the non-canonical NF-kB pathway in CD4^+^T cells during T~H~9 cell differentiation \[[@R35], [@R36]\]. The non-canonical transcription factor NF-kB (RelB) directly binds to the *Il9* promoter region and triggers *Il9* transcription under T~H~9-inducing conditions. The non-canonical alternative NF-kB pathway probably also acts together with other factors to promote T~H~9 differentiation, suggesting that it restricts the capacity of NF-kB to interact with other transcription factors at the *Il9* locus. NFAT1 (nuclear factor of activated T cells) is also required together with NF-kB for IL-9 production in CD4^+^T cells \[[@R52]\]. NFAT1 alters histone modifications and chromatin structure and restricts RelA access to the *Il9* promoter region.

Transcription factors control the secretion of specific cytokines that direct T cell differentiation and differentiating T cells integrate multiple, and sometimes conflicting, signals as they differentiate into particular subsets. This is especially true for T~H~9 cell differentiation, during which cells integrate the T~reg~-inducing TGF-β signal and the T~H~2-inducing IL-4 signal to develop a specific T~H~9 cell phenotype. TGF-β signaling induces Foxp3, which is a negative regulator of T~H~9 cell differentiation; ectopic Foxp3 expression reduces IL-9 production in T~H~9 cells \[[@R35], [@R46]\]. The IL-4 signal targets multiple genes and induces expression of the transcriptional factors IRF4, GATA3, and STAT6. IRF4 is essential for T~H~2 and T~H~17, but not T~H~9, cell differentiation. GATA3 and STAT6 are also expressed in T~H~2 cells. Thus, each of these transcriptional factors likely plays integral roles in *Il9* gene expression and production in CD4^+^T cells. Therefore, these transcription factors may not directly involved in the transcriptional regulation of the *Il9* gene, but act rather as molecules downregulating negative factors during T~H~9 differentiation, such as Foxp3, or upregulating positive factors, such as IRF4, GATA3 and STAT6, during T~H~9 cell differentiation.

T~H~9 CELL DIFFERENTIATION AND FUNCTION IN VARIOUS DISEASES {#s3}
===========================================================

T~H~9 cells have protective or pathological roles in several clinical diseases, including allergic diseases, autoimmune diseases, ulcerative colitis, infection with various pathogens, and anti-tumor immunity (Figure [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}).

![T~H~9 cells in immune-mediated diseases\
T~H~9 cells have potent protective or pathological roles in immune-mediated diseases, including allergic airway disease, inflammatory bowel diseases, autoimmune diseases (EAE, SLE), and pathogen infections.](oncotarget-07-71001-g003){#F3}

![T~**H**~9 differentiation and function in anti-tumor immunity\
T~H~9 cells have anti-tumor activity, particularly in melanoma. **A.**, iT~reg~ cells and other T cell subsets can differentiate into T~H~9 cells, which affect anti-tumor immunity. T~H~9 cells exert anti-tumor effects primarily *via* the secretion of the cytokines IL-9 **B.** and IL-21 **C.** IL-9 promotes tumor cell death directly by increasing granzyme B release and indirectly by increasing DC survival and recruitment, inducing host anti-tumor CD8^+^CTL response, or increasing Tc9 activity. IL-21 contributes to anti-tumor immunity by promoting NK cell cytolytic function and CD8^+^CTL response.](oncotarget-07-71001-g004){#F4}

T~H~9 cells in allergic airway diseases {#s3_1}
---------------------------------------

Allergic airway diseases are characterized by T~H~2-associated cytokine responses to inhaled allergens, which are orchestrated by CD4^+^T cells that produce eosinophilic lung inflammation \[[@R14]\]. In addition to the T~H~2-associated cytokines IL-4, IL-5, and IL-13, the T~H~9-associated cytokines IL-9, IL-10, and IL-21 are increased in various diseases. The T~H~9-associated genes IL-4RA, STAT6, TGFβRII, PU.1, OX40, IL-9, IL-9R, SMAD3, and IL-33 are related to asthma \[[@R53]--[@R55]\]. Airway responses and inflammatory cell levels are often evaluated in OVA-sensitized mice in asthma research \[[@R56]\]. Such studies indicate that T~H~9 cells are the primary source of IL-9 in allergic airway diseases. Additionally, increased numbers of T~H~9 cells in draining lymph nodes (DLNs) and airways strongly correlate with allergic airway diseases. T~H~9 cell-derived IL-9 can exacerbate disease conditions by increasing inflammatory cell infiltration and activation within the respiratory tract. Numbers of circulating CD4^+^T cells and IL-9 secretion are increased in serum from allergic lung disease patients compared to controls \[[@R57], [@R58]\]. Importantly, adoptive T~H~9 cell transfers increased the development of allergic airway diseases following OVA challenge, while anti-IL-9 treatment reduced disease severity \[[@R34], [@R58]--[@R60]\]. These data suggest that T~H~9 cells are critical for the induction of allergic airway disease. Similarly, our work showed that severe pathogenic lung inflammation and inflammatory cell recruitment, including eosinophil infiltration in bronchoalveolar lavage fluid (BALF), were increased in SIRT1-deficient mice compared to WT mice. Additionally, more of the CD4^+^T cells isolated from lung DLNs of SIRT1-deficient mice were IL-9^+^. Importantly, administration of an anti-IL-9 antibody reversed pathological lung tissue damage and infiltration of inflammatory cells, including eosinophils and IL-9^+^CD4^+^T cells in SIRT1-deficient mice. Thus, SIRT1 is required for the suppression of T~H~9 cell differentiation and alleviates T~H~9-associated allergic airway inflammation \[[@R51]\].

T~H~2 and T~H~9 cells may play different roles in allergic airway diseases. We propose that, during the acute inflammation phase, activated T~H~2 cells secrete multiple cytokines (e.g. IL-4, IL-13). Subsequently, various cytokines promote mast cell recruitment (IL-4, IL-9, and IL-13), eosinophil maturation (IL-5 and GM-CSF), basophil infiltration (IL-4), and the initiation of mucus metaplasia (IL-13). During the chronic phase of inflammation, repeated exposure to allergenic antigens and damaged epithelium promotes the secretion of various cytokine growth factors, including TGFβ, from epithelial cells, eosinophils, macrophages, and even mast cells. In the presence of TGFβ and IL-4, T~H~2 cells differentiate into T~H~9 cells, which promote the progression of allergic airway diseases \[[@R56], [@R61], [@R62]\].

T~H~9 cells in inflammatory bowel diseases {#s3_2}
------------------------------------------

Inflammatory bowel diseases (IBD), which include Crohn\'s diseases (CD) and ulcerative colitis (UC), are characterized by sustained inflammation, mucosal barrier defects, and frequent intestinal infections. T~H~17 and iT~reg~ cells have been implicated in the pathological mechanisms of IBD. However, studies have also shown that T~H~9 cells are involved in IBD \[[@R63]--[@R65]\]. For example, adoptive transfer of T~H~9 cells into lymphopenic recipient mice (*Rag1*^−/−^; T and B cell-deficient mice) aggravated colitis, but the underlying mechanisms remain unknown. T~H~9 cells contribute to the pathogenesis of IBD, particularly UC, by regulating intestinal barrier integrity and immunological function \[[@R21], [@R66], [@R67]\]. Furthermore, IL-9 expression is elevated in patients with active UC and is highest in patients with the most severe disease. Patients with active UC also have more intestinal CD4^+^PU.1^+^T cells than control patients or patients with CD, indicating that T~H~9 cells are at least partly responsible for IBD pathogenesis. In acute and chronic IBD mouse models, numbers of IL-9-producing cells and IL-9R levels increased during colitis. In a novel IL-9 reporter mouse, CD4^+^T cells, but not other cell types such as innate lymphoid cells, are the principal source of IL-9 in colitis. Importantly, treatment with an IL-9 antibody or IL-9 knockout in mice considerably reduces colitis, as indicated by weight loss, generation of reactive oxygen species, and clinical scores, indicating that IL-9 promotes the progression of colitis. Thus, targeting IL-9 activity may improve diagnosis and treatment in UC patients.

T~H~9 cells in autoimmune diseases {#s3_3}
----------------------------------

T~H~9 cells have been implicated in conditions that involve central nervous system inflammation, such as systemic lupus erythematosus (SLE), experimental autoimmune encephalitis (EAE), and systemic sclerosis (SSc) \[[@R19]\]. Adoptive transfer of MBP (myelin basic protein)-specific TCR transgenic T~H~9 cells into *Rag1*^−/−^ mice result in more severe EAE than transfer of T~H~1 or regular T~H~9 cells, indicating that T~H~9 cells play a critical role in the development of EAE \[[@R19], [@R68]--[@R70]\]. Due to complex regulatory mechanisms and variation in IL-9R singling in different immune cells during EAE, some studies have obtained conflicting results regarding the effects of IL-9 signaling in EAE \[[@R18], [@R43], [@R71]\]. IL-9^−/−^ mice develop less severe EAE than their WT counterparts following either immunization with myelin proteolipid protein (PLP; 180-199) peptide in the presence of Complete Freund\'s Adjuvant (CFA) or adoptive transfer of PLP (180-199) peptide-specific effector T cells from WT littermates. EAE-resistant IL-9^−/−^ mice exhibited considerably fewer infiltrating immune cells in the CNS, as well as reduced IL-17 and IFNγ expression. IL-9 deficiency also reduced PLP peptide-specific IL-17 and IFNγ levels \[[@R72], [@R73]\]. In addition, IL-9 receptor deficiency and IL-9 neutralization attenuated EAE and correlated with decreased numbers of T~H~17 cells and IL-6-producing macrophages in the central nervous system, and with decreased numbers of mast cells in regional lymph nodes \[[@R74]\]. However, some studies found that IL-9R^−/−^ EAE mice had more T~H~1 cells and T~H~17 cells than WT mice. Additionally, the inhibitory activity of T~reg~ cells was reduced in IL-9R^−/−^ mice compared to WT mice \[[@R71]\]. Together, these data suggest that IL-9 signaling may have a protective effect in EAE, although differential expression of IL-9 receptors in multiple cell types may result in more heterogeneous effects. However, the attenuation of EAE that results from IL-9 neutralization indicates that IL-9 signaling may also be pro-inflammatory.

To further investigate these possibilities, mRNA and serum IL-9 levels were assessed in the peripheral blood of SLE patients and healthy controls \[[@R75]\]. The percentage of CD4^+^IL-9^+^ T cells was elevated in SLE patients. Moreover, IL-9 expression in T cells and serum IL-9 levels in 8 untreated active SLE patients decreased 1, 2, and 3 weeks after treatment with methylprednisolone \[[@R75]\]. Thus, T~H~9 plays an important role in the pathogenesis of SLE.

T~H~9 cells in anti-pathogen infection activity {#s3_4}
-----------------------------------------------

IL-9 production in T~H~9 cells also results in anti-helminth activity. Experiments in IL-9^−/−^ mice and IL-9-fluorescent reporter mice indicate that IL-9 is crucial in the initiation of host-protective responses in the early type 2 immune response against *Nippostrongylusbrasiliensis* \[[@R15]\]. Adoptive transfer of T~H~9 cells, but not T~H~2 cells, caused rapid worm expulsion and marked basophilia and increased mast cell numbers in *Rag2*^−/−^ mice \[[@R15]\]. T~H~9 cells and IL-9 are also involved in human *Echinococcusgranulosus* infection \[[@R76]\]. Compared to healthy controls, PU.1, IL-9, and GATA-3 mRNA expression were increased in untreated patients. In addition, an increase in T~H~9 cells with the effector memory cell phenotype was found in tuberculous pleural effusion \[[@R16]\]. Taken together, these data suggest that T~H~9 cells and IL-9 a play critical and non-redundant roles in host-protective immunity against pathogenic infection.

T~H~9 CELL DIFFERENTIATION AND FUNCTION IN ANTI-TUMOR IMMUNITY {#s4}
==============================================================

T~H~9 cells regulate tumor immunity {#s4_1}
-----------------------------------

T~H~9 cells are present in metastatic pleural effusion \[[@R77]\] and human melanoma tumor-infiltrating lymphocytes \[[@R78]\]. T~H~9 also has anti-tumor properties in mice \[[@R77], [@R79]\] (Figure [4](#F4){ref-type="fig"}). In addition, melanoma tumor growth is accelerated in IL-9R^−/−^ mice, and treatment with rIL-9 inhibited this growth. Interestingly, adoptive transfer of anti-tumor T~H~9 cells inhibited tumor growth, and administration of an anti-IL-9 mAb reversed this effect. Moreover, treatment with exogenous IL-9 suppressed the growth of B16F10 melanoma and LLC-1, but not EL-4, tumors. Mechanistic investigation revealed that IL-9R expression is negligible in B16F10 and LLC-1 cells, and IL-9 had minimal effects on growth in these cells \[[@R80], [@R81]\]. However, IL-9R expression is increased in EL-4 cells, indicating an additional effect of IL-9 on tumor cells; evaluation of IL-9R expression may therefore be critical for IL-9 anti-tumor therapy. These results have been confirmed \[[@R77]\] and show that adoptive transfer of antigen-specific T~H~9 cells exerts anti-tumor effects by inhibiting the subcutaneous lung metastasis of B16F10 and T~H~9 cells. In addition, T~reg~, T~H~17, and T~H~2 cells also secrete low levels of IL-9. A considerable portion of T~H~9 cells acquire the T~H~1 phenotype and produce IFN-γ *in vivo* \[[@R82], [@R83]\]. T~H~9 cell plasticity therefore plays a role in various pathological processes, including cancer.

Our studies also indicate that T~H~9 cells contribute to anti-tumor immunity. Naïve T cells isolated from WT or SIRT1-deficient mice were differentiated under T~H~9-inducing conditions and transferred into *Rag*1^−/−^ mice, which were then subcutaneously injected with B16 melanoma cells. The mice that received SIRT1-deficient CD4^+^T cells developed smaller tumors than WT controls. Tumor infiltrating CD4^+^T cells isolated from the SIRT1-deficient groups had a higher IL-9^+^ ratio than the WT group. Importantly, administration of an anti-IL-9 antibody reversed the changes induced by SIRT1-deficient T~H~9 cell transfer \[[@R51]\]. These data show that SIRT1 is required for the suppression of T~H~9 differentiation, and thus inhibits T~H~9-dependent anti-tumor immunity.

Regulatory mechanisms of T~H~9 cells in anti-tumor immunity {#s4_2}
-----------------------------------------------------------

IL-9 produced by T~H~9 cells elicits anti-tumor immune responses through both direct and indirect regulatory mechanisms.

Several studies have reported direct regulatory mechanisms of T~H~9 cells. For example, IL-9 produced by CD4^+^TCells inhibits melanoma HTB-72 cell growth by upregulating p21 and TRAIL \[[@R84]\]. Most blood- and tissue-derived human memory T~H~9 cells were skin-tropic or skin-resident and co-expressed TNFα and granzyme B, suggesting that they play a pro-inflammatory role \[[@R85]\]. Two recent studies \[[@R86], [@R87]\] also demonstrated that glucocorticoid-induced TNF receptor-related protein (GITR) ligation directs the differentiation of iT~reg~ cells into T~H~9 cells and thus mediates anti-tumor immunity, indicating that reciprocal differentiation of T cell lineages is critical for the anti-tumor effects of T~H~9 cells. Cca cell extract (CT26 cells) acts as an antigen and induces T~H~2 responses in Cca-bearing mice, thus inhibiting tumor growth primarily by converting intra-Cca T~reg~s cells into T~H~9 cells \[[@R12]\]. Finally, T~H~9 cells have stronger anti-tumor effects than T~H~17 or T~H~1 cells \[[@R22]\], but the reciprocal differentiation mechanisms in these T cell lineages and their effects on tumor response require further investigation.

Indirect regulatory mechanisms of T~H~9 cells are likely also critical for anti-tumor immunity. IL-9 produced by CD4^+^T cells is responsible for increased survival and function in myeloid DCs, which contribute to anti-tumor immunity \[[@R88]\]. T~H~9 cells also induce host anti-tumor CD8^+^CTL responses by upregulating the CCL20/CCR6-dependent recruitment of dendritic cells (DCs) to local tumor tissues \[[@R77]\]. These findings suggest that T~H~9-mediated immune regulation is crucial for anti-tumor immunity. Moreover, tumor-specific IL-9-producing CD8^+^Tc9 cells also exert potent anti-tumor effects \[[@R89]\]. Tc9 cells primed by T~H~9-inducing conditions secreted different cytokines and were less cytolytic *in vitro*, but exhibited much stronger anti-tumor effects in OT-I/B16-OVA and Pmel-1/B16 melanoma mouse models. Adoptive transfer of Tc9 cells results in differentiation into IFNγ- and granzyme-B (GrzB)-producing cytolytic Tc1-like effector cells. This suggests that the anti-tumor activities of T~H~9 cells are partially due to their effects on Tc9 cells.

In addition to IL-9, IL-21 secreted by T~H~9 cells also exerts critical anti-tumor effects. IL-1β promotes the secretion of cytokines IL-9, IL-10, and IL-21 from T~H~9 cells through STAT1-IRF1-dependent mechanisms \[[@R22], [@R90], [@R91]\]. Furthermore, this IL-1β-induced T~H~9 differentiation increased IL-21, but not IL-9, secretion, and increased IL-21-dependent anti-tumor effects \[[@R92]--[@R94]\]. IL-21 stimulates IFNγ production, enhances the cytolytic activity of NK cells, and increases CD8^+^CTL activity, all of which promote anti-tumor immunity \[[@R28], [@R94]\].

CONCLUDING REMARKS {#s5}
==================

Following antigen stimulation, naïve CD4^+^T cells differentiate into one of several functional effector cell classes. In addition to the classical T~H~1 and T~H~2 lineages, T~H~17 cells have been extensively characterized. Recently, new subsets of IL-9-producing CD4^+^T cells have been induced *in vitro* by IL-4 and TGFβ and identified *in vivo*. IL-9 is a pleiotropic cytokine produced by T~H~2 cells, mast cells, and eosinophils. Due to the critical role of IL-9-producing CD4^+^T cells in immune-mediated diseases, T~H~9 cells have been extensively investigated in mouse and human studies during the past 20 years. These studies have demonstrated that T~H~9 cells contribute to both immune responses and immunopathological diseases. Moreover, they suggest that promoting or suppressing T~H~9 cell differentiation, transcriptional control, and function may provide novel treatments for T~H~9-associated inflammation, autoimmune diseases, and tumors. Specifically, administration of IL-9 antibodies effectively eliminated T~H~9 cells and ameliorated or aggravatedT~H~9-associated diseases.
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